risperidone has been researched along with Acathisia, Drug-Induced in 56 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "RBP-7000 is a sustained-release formulation of risperidone for the treatment of schizophrenia, designed to be administered by once-monthly subcutaneous injection using the ATRIGEL delivery system." | 9.22 | Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. ( Fava, M; Fudala, PJ; Heidbreder, C; Henderson, DC; Kouassi, A; Nasser, AF; Twumasi-Ankrah, P, 2016) |
| "This study was to evaluate the effects on clinical symptoms and cognitive function of switching the treatment of elderly patients with schizophrenia from risperidone to paliperidone (PAL)." | 9.19 | The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H, 2014) |
| "This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS." | 9.16 | Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012) |
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 9.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "Data on risperidone's efficacy and tolerability in adolescents with schizophrenia are scarce." | 9.10 | Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. ( Bensason, D; Carmon, E; Martin, A; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "The subjects were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a regimen of clozapine at the time of screening." | 9.08 | Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. ( Daniel, DG; Goldberg, TE; Kleinman, JE; Lubick, LJ; Pickar, D; Weinberger, DR; Williams, TS, 1996) |
| "These results suggest that risperidone augmentation is effective and well tolerated in patients with SRI-refractory obsessive-compulsive disorder." | 9.08 | Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. ( Baxter, LR; Bystritsky, A; Saxena, S; Wang, D, 1996) |
| "A prospective, open-label study in a 400-bed state psychiatric hospital evaluated change in therapeutic response among ten patients with treatment-resistant schizophrenia who were switched from clozapine to risperidone." | 7.69 | Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. ( Crismon, ML; Dorson, PG; Pousson, C; Still, DJ, 1996) |
| " The aim of the present study was to analyze on a single case basis the relationship between a sudden increase in suicidality, anxiety symptoms, medication dosing and clinician- and patient-rated akathisia." | 6.77 | The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. ( Bauer, M; Doucette, S; Lewitzka, U; Meyer, S; Möller, HJ; Musil, R; Riedel, M; Schennach, R; Seemüller, F, 2012) |
| "Aripiprazole treatment led to significantly more akathisia incidence in the AD group, compared with the SCZ group." | 6.48 | Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. ( Moteshafi, H; Stip, E, 2012) |
| "In the antipsychotic treatment of schizophrenia with little medication history, especially in drug-naïve cases, predictors of side effects are important." | 5.51 | Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. ( Sakamoto, S; Sato, K; So, R; Tsukahara, M; Yoshimura, B; Yoshimura, Y, 2019) |
| "RBP-7000 is a sustained-release formulation of risperidone for the treatment of schizophrenia, designed to be administered by once-monthly subcutaneous injection using the ATRIGEL delivery system." | 5.22 | Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. ( Fava, M; Fudala, PJ; Heidbreder, C; Henderson, DC; Kouassi, A; Nasser, AF; Twumasi-Ankrah, P, 2016) |
| "This study was to evaluate the effects on clinical symptoms and cognitive function of switching the treatment of elderly patients with schizophrenia from risperidone to paliperidone (PAL)." | 5.19 | The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H, 2014) |
| "This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS." | 5.16 | Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012) |
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 5.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "Data on risperidone's efficacy and tolerability in adolescents with schizophrenia are scarce." | 5.10 | Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. ( Bensason, D; Carmon, E; Martin, A; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "The subjects were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a regimen of clozapine at the time of screening." | 5.08 | Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. ( Daniel, DG; Goldberg, TE; Kleinman, JE; Lubick, LJ; Pickar, D; Weinberger, DR; Williams, TS, 1996) |
| "These results suggest that risperidone augmentation is effective and well tolerated in patients with SRI-refractory obsessive-compulsive disorder." | 5.08 | Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. ( Baxter, LR; Bystritsky, A; Saxena, S; Wang, D, 1996) |
| " Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia." | 4.80 | Adverse events related to olanzapine. ( Conley, RR; Meltzer, HY, 2000) |
| "In this study, 15 patients with schizophrenia receiving risperidone were switched to PAL and treated for 12 weeks." | 3.80 | Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Otomo, M; Suzuki, H, 2014) |
| "Sixty-seven outpatients with schizophrenia receiving stable doses of risperidone or haloperidol were evaluated for akathisia and other extrapyramidal side effects." | 3.74 | Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. ( Byun, HJ; Kim, JH, 2007) |
| "The present study compares the subjective responses of patients in the stable phase of schizophrenia being treated with either olanzapine or risperidone." | 3.73 | Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey. ( McGrath, BM; Tempier, RP, 2005) |
| "A prospective, open-label study in a 400-bed state psychiatric hospital evaluated change in therapeutic response among ten patients with treatment-resistant schizophrenia who were switched from clozapine to risperidone." | 3.69 | Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. ( Crismon, ML; Dorson, PG; Pousson, C; Still, DJ, 1996) |
| " The aim of the present study was to analyze on a single case basis the relationship between a sudden increase in suicidality, anxiety symptoms, medication dosing and clinician- and patient-rated akathisia." | 2.77 | The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. ( Bauer, M; Doucette, S; Lewitzka, U; Meyer, S; Möller, HJ; Musil, R; Riedel, M; Schennach, R; Seemüller, F, 2012) |
| "Suicidal ideation was significantly associated with clinician observed akathisia, depressed mood, younger age, and use of propranolol." | 2.77 | Akathisia and suicidal ideation in first-episode schizophrenia. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingenberg, S; Klosterkötter, J; Lewitzka, U; Maier, W; Mayr, A; Möller, HJ; Musil, R; Ohmann, C; Riedel, M; Schennach, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| " Adverse effects (n = 15), inadequate efficacy (n = 14), or study nonadherence (n = 8) were the most common reasons for discontinuation." | 2.75 | Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. ( Findling, RL; Frazier, JA; Hamer, RM; Hlastala, S; Johnson, JL; Kaufman, EM; Lieberman, JA; Lingler, J; Maloney, AE; McClellan, J; McNamara, NK; Noyes, N; Pierson, L; Puglia, M; Ritz, L; Sikich, L; Vitiello, B, 2010) |
| "Olanzapine-treated patients had greater HAM-D-21 (p = ." | 2.72 | Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. ( Baker, RW; Brown, EB; Jamal, HH; Perlis, RH; Schuh, LM; Tohen, M; Zarate, CA, 2006) |
| "Treatment with risperidone for either 3 or 6 weeks in an open trial significantly reduced total and subscales scores on the PANSS and on the PTSD-I and CGI-S when compared to baseline scores in patients with psychotic PTSD." | 2.71 | Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. ( Kozarić-Kovacić, D; Mück-Seler, D; Pivac, N; Rothbaum, BO, 2005) |
| "Patients with delirium are frequently treated with antipsychotic medications that are well known to induce akathisia as a side effect." | 2.53 | Antipsychotic-induced akathisia in delirium: A systematic review. ( Alici, Y; Forcen, FE; Matsoukas, K, 2016) |
| "Aripiprazole treatment led to significantly more akathisia incidence in the AD group, compared with the SCZ group." | 2.48 | Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. ( Moteshafi, H; Stip, E, 2012) |
| " Surprisingly, there has been little relationship between the pivotal trials designed for FDA approval and current dosing strategies in broader clinical settings." | 2.41 | New antipsychotic medications: more than old wine and new bottles. ( Schulz, SC, 2000) |
| "Although the risk of developing lethal neuroleptic malignant syndrome may be diminished with atypical drugs, clinicians must remain alert to the signs of this disorder." | 2.41 | Movement disorders associated with atypical antipsychotic drugs. ( Campbell, EC; Caroff, SN; Mann, SC; Sullivan, KA, 2002) |
| "Risperidone has these pharmacologic properties." | 2.39 | Extrapyramidal side effects and tolerability of risperidone: a review. ( Owens, DG, 1994) |
| "In the antipsychotic treatment of schizophrenia with little medication history, especially in drug-naïve cases, predictors of side effects are important." | 1.51 | Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. ( Sakamoto, S; Sato, K; So, R; Tsukahara, M; Yoshimura, B; Yoshimura, Y, 2019) |
| " EPS were assessed at baseline and 4, 8, and 12 weeks after naturalistic SGA initiation for schizophrenia, mood, disruptive behavior, and autism spectrum disorders using the Simpson-Angus Scale (SAS), Barnes Akathisia Scale, Abnormal Involuntary Movement Scale (AIMS), and Treatment Emergent Side Effect Scale." | 1.42 | Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. ( Al-Jadiri, A; Azzo, S; Carbon, M; Correll, CU; Kane, JM; Kapoor, S; Saito, E; Sarkaria, T; Sheridan, E, 2015) |
| "Mirtazapine is a potent antagonist of central alpha(2) auto- and hetero-adrenergic receptors, as well as an antagonist of 5-HT(2A/2C), 5-HT(3), and histaminergic H(1) postsynaptic receptors." | 1.33 | Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine. ( Chandra, PS; Chaturvedi, SK; Gupta, A; Prabhu, SC; Ranjan, S, 2006) |
| "Risperidone is a recently introduced neuroleptic distinguished by a decreased incidence of extrapyramidal side effects (EPS)." | 1.29 | The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. ( Houle, S; Kapur, S; Remington, G; Wilson, AA; Zipursky, RB, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (19.64) | 18.2507 |
| 2000's | 30 (53.57) | 29.6817 |
| 2010's | 15 (26.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Juncal-Ruiz, M | 1 |
| Ramirez-Bonilla, M | 1 |
| Gomez-Arnau, J | 1 |
| Ortiz-Garcia de la Foz, V | 1 |
| Suarez-Pinilla, P | 1 |
| Martinez-Garcia, O | 1 |
| Neergaard, KD | 1 |
| Tabares-Seisdedos, R | 1 |
| Crespo-Facorro, B | 1 |
| Yoshimura, B | 1 |
| Sato, K | 1 |
| Sakamoto, S | 1 |
| Tsukahara, M | 1 |
| Yoshimura, Y | 1 |
| So, R | 1 |
| Soundarrajan, G | 1 |
| Chogtu, B | 1 |
| Krishna, V | 1 |
| Kamath G, A | 1 |
| Murugesan, M | 1 |
| Suzuki, H | 2 |
| Gen, K | 2 |
| Inoue, Y | 2 |
| Hibino, H | 2 |
| Mikami, A | 2 |
| Matsumoto, H | 2 |
| Mikami, K | 2 |
| Otomo, M | 1 |
| Forcen, FE | 1 |
| Matsoukas, K | 1 |
| Alici, Y | 1 |
| Carbon, M | 1 |
| Kapoor, S | 1 |
| Sheridan, E | 1 |
| Al-Jadiri, A | 1 |
| Azzo, S | 1 |
| Sarkaria, T | 1 |
| Kane, JM | 2 |
| Saito, E | 1 |
| Correll, CU | 1 |
| Nasser, AF | 1 |
| Henderson, DC | 1 |
| Fava, M | 1 |
| Fudala, PJ | 1 |
| Twumasi-Ankrah, P | 1 |
| Kouassi, A | 1 |
| Heidbreder, C | 1 |
| Lamkin, S | 1 |
| Buhl, D | 1 |
| Moncrieff, J | 1 |
| Cohen, D | 1 |
| Mason, JP | 1 |
| Caykoylu, A | 1 |
| Ekinci, O | 1 |
| Yilmaz, E | 1 |
| Chen, CK | 1 |
| Wu, JH | 1 |
| Findling, RL | 1 |
| Johnson, JL | 1 |
| McClellan, J | 1 |
| Frazier, JA | 1 |
| Vitiello, B | 1 |
| Hamer, RM | 1 |
| Lieberman, JA | 2 |
| Ritz, L | 1 |
| McNamara, NK | 1 |
| Lingler, J | 1 |
| Hlastala, S | 1 |
| Pierson, L | 1 |
| Puglia, M | 1 |
| Maloney, AE | 1 |
| Kaufman, EM | 1 |
| Noyes, N | 1 |
| Sikich, L | 1 |
| Kim, JH | 2 |
| Byun, HJ | 2 |
| Fang, M | 1 |
| Chen, H | 1 |
| Li, LH | 1 |
| Wu, R | 1 |
| Li, Y | 1 |
| Liu, L | 1 |
| Ye, M | 1 |
| Huang, J | 1 |
| Zhu, S | 1 |
| Wang, G | 1 |
| Zhang, Q | 1 |
| Zheng, H | 1 |
| Zhang, L | 1 |
| Wang, B | 1 |
| Zhou, J | 1 |
| Zhao, JP | 1 |
| Kaufmann, A | 1 |
| Boesch, S | 1 |
| Fleischhacker, WW | 2 |
| Hofer, A | 1 |
| Seemüller, F | 2 |
| Lewitzka, U | 2 |
| Bauer, M | 1 |
| Meyer, S | 1 |
| Musil, R | 2 |
| Schennach, R | 2 |
| Riedel, M | 2 |
| Doucette, S | 1 |
| Möller, HJ | 2 |
| Moteshafi, H | 1 |
| Stip, E | 1 |
| Mayr, A | 1 |
| Jäger, M | 1 |
| Maier, W | 1 |
| Klingenberg, S | 1 |
| Heuser, I | 1 |
| Klosterkötter, J | 1 |
| Gastpar, M | 1 |
| Schmitt, A | 1 |
| Schlösser, R | 1 |
| Schneider, F | 1 |
| Ohmann, C | 1 |
| Gaebel, W | 1 |
| Bullock, R | 1 |
| Saharan, A | 1 |
| Shimizu, E | 1 |
| Watanabe, H | 1 |
| Iyo, M | 1 |
| Sharkey, L | 1 |
| O'Donovan, A | 1 |
| Nakagawa, S | 1 |
| Koyama, T | 1 |
| Zalsman, G | 1 |
| Carmon, E | 1 |
| Martin, A | 1 |
| Bensason, D | 1 |
| Weizman, A | 2 |
| Tyano, S | 1 |
| Barrett, SL | 1 |
| Bell, R | 1 |
| Watson, D | 1 |
| King, DJ | 1 |
| Addington, DE | 1 |
| Pantelis, C | 1 |
| Dineen, M | 1 |
| Benattia, I | 1 |
| Romano, SJ | 1 |
| Vorel, SK | 1 |
| Bos, F | 1 |
| Vorel-Havelkova, E | 1 |
| Brombacher, PJ | 1 |
| Honer, WG | 1 |
| Kopala, LC | 1 |
| Rabinowitz, J | 1 |
| Kozarić-Kovacić, D | 1 |
| Pivac, N | 1 |
| Mück-Seler, D | 1 |
| Rothbaum, BO | 1 |
| McGrath, BM | 1 |
| Tempier, RP | 1 |
| Ranjan, S | 1 |
| Chandra, PS | 1 |
| Chaturvedi, SK | 1 |
| Prabhu, SC | 1 |
| Gupta, A | 1 |
| Mozes, T | 1 |
| Ebert, T | 1 |
| Michal, SE | 1 |
| Spivak, B | 1 |
| Perlis, RH | 1 |
| Baker, RW | 1 |
| Zarate, CA | 1 |
| Brown, EB | 1 |
| Schuh, LM | 1 |
| Jamal, HH | 1 |
| Tohen, M | 1 |
| Sabuncuoglu, O | 1 |
| Cotter, PE | 1 |
| O'Keeffe, ST | 1 |
| Lindström, E | 2 |
| Eberhard, J | 2 |
| Levander, S | 2 |
| Bratti, IM | 1 |
| Marder, SR | 1 |
| Owens, DG | 1 |
| Byerly, MJ | 1 |
| Greer, RA | 1 |
| Evans, DL | 1 |
| Kapur, S | 1 |
| Remington, G | 1 |
| Zipursky, RB | 1 |
| Wilson, AA | 1 |
| Houle, S | 1 |
| Daniel, DG | 1 |
| Goldberg, TE | 1 |
| Weinberger, DR | 1 |
| Kleinman, JE | 1 |
| Pickar, D | 1 |
| Lubick, LJ | 1 |
| Williams, TS | 1 |
| Saxena, S | 1 |
| Wang, D | 1 |
| Bystritsky, A | 1 |
| Baxter, LR | 1 |
| Rosebush, PI | 1 |
| Kennedy, K | 1 |
| Dalton, B | 1 |
| Mazurek, MF | 1 |
| Still, DJ | 1 |
| Dorson, PG | 1 |
| Crismon, ML | 1 |
| Pousson, C | 1 |
| Miller, CH | 1 |
| Mohr, F | 1 |
| Umbricht, D | 1 |
| Woerner, M | 1 |
| Meyer, JM | 1 |
| Marsh, J | 1 |
| Simpson, G | 1 |
| Meares, S | 1 |
| Draper, B | 1 |
| Schulz, SC | 1 |
| Simpson, GM | 1 |
| Conley, RR | 1 |
| Meltzer, HY | 1 |
| Hansen, L | 1 |
| Wilkinson, DG | 1 |
| Wirshing, WC | 1 |
| Caroff, SN | 1 |
| Mann, SC | 1 |
| Campbell, EC | 1 |
| Sullivan, KA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Treatment of Schizophrenia and Related Disorders in Children and Adolescents[NCT00053703] | Phase 4 | 116 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia[NCT00159120] | Phase 4 | 71 participants (Anticipated) | Interventional | 2001-11-30 | Completed | ||
| Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years[NCT00230893] | 99 participants | Observational | 2005-07-31 | Completed | |||
| Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade[NCT00233467] | 0 participants (Actual) | Observational | 2005-09-01 | Withdrawn (stopped due to Funding expired; no subjects enrolled as this was a retrospective chart review) | |||
| Quetiapine in the Treatment of Psychotic Depression - a Pilot Study[NCT00751504] | Phase 3 | 16 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Barnes Akathisia Scale is a clinician rated scale which considers information based on observation of the participant as well as participant report. The scale includes 3 items rated between 0- none to 3 severe and 1 summary item rated between 0 none to 5 severe. All items are summed to obtain the total score. The minimal total score is 0 and the maximal score is 14 with higher scores reflecting more severe akathisia. A score of 4 or more is clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | 0.19 |
| Risperidone | 0.41 |
| Molindone | 1.23 |
Change from baseline in Body Mass Index Change, kg/m2, at week 8, last observation was carried forward for individuals who withdrew from treatment early. (NCT00053703)
Timeframe: 8 weeks
| Intervention | kg/m2 (Mean) |
|---|---|
| Olanzapine | 1.27 |
| Risperidone | 2.20 |
| Molindone | 0.15 |
The PANSS (described above) includes 7 items that reflect negative psychotic symptoms such as amotivation and social withdrawal. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -5.3 |
| Risperidone | -5.1 |
| Molindone | -5.8 |
The PANSS (described above) includes 7 items that reflect positive psychotic symptoms such as hallucinations and delusions. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -8.9 |
| Risperidone | -8.4 |
| Molindone | -8.8 |
Assessed with the Positive and Negative Syndrome Scale in which a clinician rates various psychotic symptoms on the basis of observation of the participant, interview with the participant, and review of all other available information including informant reports. The scale consists of 30 items which are rated categorically between 1 - no symptoms to 7 - extreme symptoms. The minimal score is 0 and the maximal score is 210, with higher scores reflecting more symptoms. Typically scores > that 60 are considered clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -26.6 |
| Risperidone | -23.7 |
| Molindone | -27.0 |
change in weight from baseline to week 8 in kg (NCT00053703)
Timeframe: 8 weeks
| Intervention | Kg (Mean) |
|---|---|
| Olanzapine | 6.12 |
| Risperidone | 3.64 |
| Molindone | 0.34 |
12 reviews available for risperidone and Acathisia, Drug-Induced
| Article | Year |
|---|---|
Antipsychotic-induced akathisia in delirium: A systematic review.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Delirium; Haloperidol; Humans; Prevalence; Risperidon | 2016 |
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
Topics: Adult; Affective Disorders, Psychotic; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; | 2012 |
Atypical antipsychotics: experience and use in the elderly.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; | 2002 |
[Extrapyramidal syndrome].
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazep | 2003 |
Chronic restlessness with antipsychotics.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Chro | 2007 |
Extrapyramidal side effects and tolerability of risperidone: a review.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; D | 1994 |
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
New antipsychotic medications: more than old wine and new bottles.
Topics: Agranulocytosis; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzot | 2000 |
The treatment of tardive dyskinesia and tardive dystonia.
Topics: Adult; Akathisia, Drug-Induced; Algorithms; Antipsychotic Agents; Benzodiazepines; Clozapine; Decisi | 2000 |
Adverse events related to olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass In | 2000 |
Movement disorders associated with neuroleptic treatment.
Topics: Age Factors; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; | 2001 |
Movement disorders associated with atypical antipsychotic drugs.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 2002 |
17 trials available for risperidone and Acathisia, Drug-Induced
| Article | Year |
|---|---|
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloper | 2017 |
The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial.
Topics: Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Cognition Disorders; Drug Substitution; Dyskine | 2014 |
Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Delayed-Action Preparations; Double-Blind Me | 2016 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia.
Topics: Administration, Oral; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; China; Clonazepam; Diagn | 2012 |
The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone.
Topics: Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Female; Halo | 2012 |
Akathisia and suicidal ideation in first-episode schizophrenia.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Depression; Double-Blind Method; | 2012 |
Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug- | 2003 |
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies | 2004 |
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Bli | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Body Weight; Child; Dose | 2006 |
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Benzodiazepines; Bipolar Disor | 2006 |
Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Female; Humans; Longitudinal Studies; Ma | 2007 |
Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study.
Topics: Akathisia, Drug-Induced; Ambulatory Care; Clozapine; Cognition Disorders; Cross-Over Studies; Humans | 1996 |
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Topics: Adult; Akathisia, Drug-Induced; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle | 1996 |
The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
Topics: Acute Disease; Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Antipsychotic Agents; Ba | 1998 |
27 other studies available for risperidone and Acathisia, Drug-Induced
| Article | Year |
|---|---|
Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; I | 2019 |
Akathisia Induced by Abrupt Withdrawal of Risperidone: A Case Report.
Topics: Adolescent; Akathisia, Drug-Induced; Female; Humans; Risperidone; Substance Withdrawal Syndrome | 2019 |
Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Blood Chemical Analysis; Chromatography, Liquid; Fema | 2014 |
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dru | 2015 |
Extrapyramidal side effects: could you identify them in the emergency department?
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dopamine Antagonists; Dyskinesi | 2009 |
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.
Topics: Adult; Affect; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety Disorders; Attitude to Health; | 2009 |
Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Qui | 2009 |
Improvement of risperidone-related tardive parkinsonism with a switch to aripiprazole.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Middle Aged; Parkinson | 2009 |
The relationship between akathisia and subjective tolerability in patients with schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Autonomic Nervous System Diseases; Basal Gangl | 2010 |
Management of a risperidone-induced tardive Pisa syndrome: a case report.
Topics: Abdomen; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Drug Monitoring; Dystonia; Female; Hu | 2012 |
Delayed-onset nocturnal akathisia due to risperidone and levomepromazine: a case report.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Circadian Rhythm; Female; Humans; Methotrimeprazine; | 2002 |
Sexual disinhibition induced by risperidone in a child.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Biperiden; Child; Humans; Male; Muscarinic Antagonist | 2002 |
Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers.
Topics: Acoustic Stimulation; Administration, Oral; Adult; Akathisia, Drug-Induced; Amisulpride; Blood Press | 2004 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dementia; Humans; Neuroleptic Malignant Syndrome; Ris | 2005 |
Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Attitude; Benzodiazepines; Cross-Section | 2005 |
Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Mianser | 2006 |
Risperidone-to-methylphenidate switch reaction in children: three cases.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit and Disruptive Behavior | 2007 |
Improvement in neuroleptic-induced akathisia with intravenous iron treatment in a patient with iron deficiency.
Topics: Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Humans; Infusions, Intravenous; Iron; Iron Defi | 2007 |
Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Fem | 2007 |
Clinical decision-making during 5 years of antipsychotic treatment.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Attitude; Female; Humans; Lo | 2007 |
Behavioral stimulation associated with risperidone initiation.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Benzodiazepines; Confusion; Female; Humans; | 1995 |
The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
Topics: Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Humans; Isoxazoles; Male; Piperidines; Recep | 1995 |
Protracted akathisia after risperidone withdrawal.
Topics: Aged; Akathisia, Drug-Induced; Drug Administration Schedule; Female; Humans; Psychotic Disorders; Ri | 1997 |
Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chronic Disease; Clozapine; Drug Administratio | 1996 |
Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, D | 1998 |
Treatment of vocally disruptive behaviour of multifactorial aetiology.
Topics: Aged; Akathisia, Drug-Induced; Behavior Therapy; Dementia; Depression; Female; Homes for the Aged; H | 1999 |
Drug induced akathisia, suicidal ideation and its treatment in the elderly.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antipsychotic Agents; Depressive Disorder; Drug Th | 2001 |